img

Global Insulin Biosimilars Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Insulin Biosimilars Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.
The global Insulin Biosimilars market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Insulin Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The China market for Insulin Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The Europe market for Insulin Biosimilars is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034..
The global key manufacturers of Insulin Biosimilars include Sanofi S.A., Boehringer Ingelheim, Eli Lilly & Co., Novo Nordisk A/S, Biocon, Geropharm, Wockhardt, Gan&Lee Pharmaceuticals and The United Laboratories International, etc. In 2024, the global top five players hold a share approximately % in sales volume, and in term of revenue of Insulin Biosimilars, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Insulin Biosimilars by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Insulin Biosimilars market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Insulin Biosimilars market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Sanofi S.A.
Boehringer Ingelheim
Eli Lilly & Co.
Novo Nordisk A/S
Biocon
Geropharm
Wockhardt
Gan&Lee Pharmaceuticals
The United Laboratories International
Tonghua Dongbao Pharmaceutical
By Type
Rapid-Acting Biosimilars
Long-Acting Biosimilars
Premixed Biosimilars
By Application
Type I Diabetes
Type II Diabetes
Sales by Region
North America
United States
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Insulin Biosimilars in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Insulin Biosimilars manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Insulin Biosimilars sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Insulin Biosimilars Definition
1.2 Market by Type
1.2.1 Global Insulin Biosimilars Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Rapid-Acting Biosimilars
1.2.3 Long-Acting Biosimilars
1.2.4 Premixed Biosimilars
1.3 Market Segment by Application
1.3.1 Global Insulin Biosimilars Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Type I Diabetes
1.3.3 Type II Diabetes
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Insulin Biosimilars Sales
2.1 Global Insulin Biosimilars Revenue Estimates and Forecasts 2018-2034
2.2 Global Insulin Biosimilars Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Insulin Biosimilars Revenue by Region
2.3.1 Global Insulin Biosimilars Revenue by Region (2018-2023)
2.3.2 Global Insulin Biosimilars Revenue by Region (2024-2034)
2.4 Global Insulin Biosimilars Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Insulin Biosimilars Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Insulin Biosimilars Sales Quantity by Region
2.6.1 Global Insulin Biosimilars Sales Quantity by Region (2018-2023)
2.6.2 Global Insulin Biosimilars Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Insulin Biosimilars Sales Quantity by Manufacturers
3.1.1 Global Insulin Biosimilars Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Insulin Biosimilars Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Insulin Biosimilars Sales in 2024
3.2 Global Insulin Biosimilars Revenue by Manufacturers
3.2.1 Global Insulin Biosimilars Revenue by Manufacturers (2018-2023)
3.2.2 Global Insulin Biosimilars Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Insulin Biosimilars Revenue in 2024
3.3 Global Insulin Biosimilars Sales Price by Manufacturers
3.4 Global Key Players of Insulin Biosimilars, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Insulin Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Insulin Biosimilars, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Insulin Biosimilars, Product Offered and Application
3.8 Global Key Manufacturers of Insulin Biosimilars, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Insulin Biosimilars Sales Quantity by Type
4.1.1 Global Insulin Biosimilars Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Insulin Biosimilars Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Insulin Biosimilars Sales Quantity Market Share by Type (2018-2034)
4.2 Global Insulin Biosimilars Revenue by Type
4.2.1 Global Insulin Biosimilars Historical Revenue by Type (2018-2023)
4.2.2 Global Insulin Biosimilars Forecasted Revenue by Type (2024-2034)
4.2.3 Global Insulin Biosimilars Revenue Market Share by Type (2018-2034)
4.3 Global Insulin Biosimilars Price by Type
4.3.1 Global Insulin Biosimilars Price by Type (2018-2023)
4.3.2 Global Insulin Biosimilars Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Insulin Biosimilars Sales Quantity by Application
5.1.1 Global Insulin Biosimilars Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Insulin Biosimilars Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Insulin Biosimilars Sales Quantity Market Share by Application (2018-2034)
5.2 Global Insulin Biosimilars Revenue by Application
5.2.1 Global Insulin Biosimilars Historical Revenue by Application (2018-2023)
5.2.2 Global Insulin Biosimilars Forecasted Revenue by Application (2024-2034)
5.2.3 Global Insulin Biosimilars Revenue Market Share by Application (2018-2034)
5.3 Global Insulin Biosimilars Price by Application
5.3.1 Global Insulin Biosimilars Price by Application (2018-2023)
5.3.2 Global Insulin Biosimilars Price Forecast by Application (2024-2034)
6 North America
6.1 North America Insulin Biosimilars Sales by Company
6.1.1 North America Insulin Biosimilars Revenue by Company (2018-2023)
6.1.2 North America Insulin Biosimilars Sales Quantity by Company (2018-2023)
6.2 North America Insulin Biosimilars Market Size by Type
6.2.1 North America Insulin Biosimilars Sales Quantity by Type (2018-2034)
6.2.2 North America Insulin Biosimilars Revenue by Type (2018-2034)
6.3 North America Insulin Biosimilars Market Size by Application
6.3.1 North America Insulin Biosimilars Sales Quantity by Application (2018-2034)
6.3.2 North America Insulin Biosimilars Revenue by Application (2018-2034)
6.4 North America Insulin Biosimilars Market Size by Country
6.4.1 North America Insulin Biosimilars Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Insulin Biosimilars Revenue by Country (2018-2034)
6.4.3 North America Insulin Biosimilars Sales Quantity by Country (2018-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Insulin Biosimilars Sales by Company
7.1.1 Europe Insulin Biosimilars Sales Quantity by Company (2018-2023)
7.1.2 Europe Insulin Biosimilars Revenue by Company (2018-2023)
7.2 Europe Insulin Biosimilars Market Size by Type
7.2.1 Europe Insulin Biosimilars Sales Quantity by Type (2018-2034)
7.2.2 Europe Insulin Biosimilars Revenue by Type (2018-2034)
7.3 Europe Insulin Biosimilars Market Size by Application
7.3.1 Europe Insulin Biosimilars Sales Quantity by Application (2018-2034)
7.3.2 Europe Insulin Biosimilars Revenue by Application (2018-2034)
7.4 Europe Insulin Biosimilars Market Size by Country
7.4.1 Europe Insulin Biosimilars Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Insulin Biosimilars Revenue by Country (2018-2034)
7.4.3 Europe Insulin Biosimilars Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Insulin Biosimilars Sales by Company
8.1.1 China Insulin Biosimilars Sales Quantity by Company (2018-2023)
8.1.2 China Insulin Biosimilars Revenue by Company (2018-2023)
8.2 China Insulin Biosimilars Market Size by Type
8.2.1 China Insulin Biosimilars Sales Quantity by Type (2018-2034)
8.2.2 China Insulin Biosimilars Revenue by Type (2018-2034)
8.3 China Insulin Biosimilars Market Size by Application
8.3.1 China Insulin Biosimilars Sales Quantity by Application (2018-2034)
8.3.2 China Insulin Biosimilars Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Insulin Biosimilars Sales by Company
9.1.1 APAC Insulin Biosimilars Sales Quantity by Company (2018-2023)
9.1.2 APAC Insulin Biosimilars Revenue by Company (2018-2023)
9.2 APAC Insulin Biosimilars Market Size by Type
9.2.1 APAC Insulin Biosimilars Sales Quantity by Type (2018-2034)
9.2.2 APAC Insulin Biosimilars Revenue by Type (2018-2034)
9.3 APAC Insulin Biosimilars Market Size by Application
9.3.1 APAC Insulin Biosimilars Sales Quantity by Application (2018-2034)
9.3.2 APAC Insulin Biosimilars Revenue by Application (2018-2034)
9.4 APAC Insulin Biosimilars Market Size by Region
9.4.1 APAC Insulin Biosimilars Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Insulin Biosimilars Revenue by Region (2018-2034)
9.4.3 APAC Insulin Biosimilars Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Insulin Biosimilars Sales by Company
10.1.1 Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Insulin Biosimilars Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Insulin Biosimilars Market Size by Type
10.2.1 Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Insulin Biosimilars Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Insulin Biosimilars Market Size by Application
10.3.1 Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Insulin Biosimilars Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Insulin Biosimilars Market Size by Country
10.4.1 Middle East, Africa and Latin America Insulin Biosimilars Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Insulin Biosimilars Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Sanofi S.A.
11.1.1 Sanofi S.A. Company Information
11.1.2 Sanofi S.A. Overview
11.1.3 Sanofi S.A. Insulin Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Sanofi S.A. Insulin Biosimilars Products and Services
11.1.5 Sanofi S.A. Insulin Biosimilars SWOT Analysis
11.1.6 Sanofi S.A. Recent Developments
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Information
11.2.2 Boehringer Ingelheim Overview
11.2.3 Boehringer Ingelheim Insulin Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Boehringer Ingelheim Insulin Biosimilars Products and Services
11.2.5 Boehringer Ingelheim Insulin Biosimilars SWOT Analysis
11.2.6 Boehringer Ingelheim Recent Developments
11.3 Eli Lilly & Co.
11.3.1 Eli Lilly & Co. Company Information
11.3.2 Eli Lilly & Co. Overview
11.3.3 Eli Lilly & Co. Insulin Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Eli Lilly & Co. Insulin Biosimilars Products and Services
11.3.5 Eli Lilly & Co. Insulin Biosimilars SWOT Analysis
11.3.6 Eli Lilly & Co. Recent Developments
11.4 Novo Nordisk A/S
11.4.1 Novo Nordisk A/S Company Information
11.4.2 Novo Nordisk A/S Overview
11.4.3 Novo Nordisk A/S Insulin Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Novo Nordisk A/S Insulin Biosimilars Products and Services
11.4.5 Novo Nordisk A/S Insulin Biosimilars SWOT Analysis
11.4.6 Novo Nordisk A/S Recent Developments
11.5 Biocon
11.5.1 Biocon Company Information
11.5.2 Biocon Overview
11.5.3 Biocon Insulin Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Biocon Insulin Biosimilars Products and Services
11.5.5 Biocon Insulin Biosimilars SWOT Analysis
11.5.6 Biocon Recent Developments
11.6 Geropharm
11.6.1 Geropharm Company Information
11.6.2 Geropharm Overview
11.6.3 Geropharm Insulin Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Geropharm Insulin Biosimilars Products and Services
11.6.5 Geropharm Insulin Biosimilars SWOT Analysis
11.6.6 Geropharm Recent Developments
11.7 Wockhardt
11.7.1 Wockhardt Company Information
11.7.2 Wockhardt Overview
11.7.3 Wockhardt Insulin Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Wockhardt Insulin Biosimilars Products and Services
11.7.5 Wockhardt Insulin Biosimilars SWOT Analysis
11.7.6 Wockhardt Recent Developments
11.8 Gan&Lee Pharmaceuticals
11.8.1 Gan&Lee Pharmaceuticals Company Information
11.8.2 Gan&Lee Pharmaceuticals Overview
11.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Gan&Lee Pharmaceuticals Insulin Biosimilars Products and Services
11.8.5 Gan&Lee Pharmaceuticals Insulin Biosimilars SWOT Analysis
11.8.6 Gan&Lee Pharmaceuticals Recent Developments
11.9 The United Laboratories International
11.9.1 The United Laboratories International Company Information
11.9.2 The United Laboratories International Overview
11.9.3 The United Laboratories International Insulin Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 The United Laboratories International Insulin Biosimilars Products and Services
11.9.5 The United Laboratories International Insulin Biosimilars SWOT Analysis
11.9.6 The United Laboratories International Recent Developments
11.10 Tonghua Dongbao Pharmaceutical
11.10.1 Tonghua Dongbao Pharmaceutical Company Information
11.10.2 Tonghua Dongbao Pharmaceutical Overview
11.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Products and Services
11.10.5 Tonghua Dongbao Pharmaceutical Insulin Biosimilars SWOT Analysis
11.10.6 Tonghua Dongbao Pharmaceutical Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Insulin Biosimilars Value Chain Analysis
12.2 Insulin Biosimilars Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Insulin Biosimilars Production Mode & Process
12.4 Insulin Biosimilars Sales and Marketing
12.4.1 Insulin Biosimilars Sales Channels
12.4.2 Insulin Biosimilars Distributors
12.5 Insulin Biosimilars Customers
13 Market Dynamics
13.1 Insulin Biosimilars Industry Trends
13.2 Insulin Biosimilars Market Drivers
13.3 Insulin Biosimilars Market Challenges
13.4 Insulin Biosimilars Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Insulin Biosimilars Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Rapid-Acting Biosimilars
Table 3. Major Manufacturers of Long-Acting Biosimilars
Table 4. Major Manufacturers of Premixed Biosimilars
Table 5. Global Insulin Biosimilars Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Insulin Biosimilars Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. Global Insulin Biosimilars Revenue by Region (2018-2023) & (US$ Million)
Table 8. Global Insulin Biosimilars Revenue Market Share by Region (2018-2023)
Table 9. Global Insulin Biosimilars Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Insulin Biosimilars Revenue Market Share by Region (2024-2034)
Table 11. Global Insulin Biosimilars Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 12. Global Insulin Biosimilars Sales by Region (2018-2023) & (K Units)
Table 13. Global Insulin Biosimilars Sales Market Share by Region (2018-2023)
Table 14. Global Insulin Biosimilars Sales by Region (2024-2034) & (K Units)
Table 15. Global Insulin Biosimilars Sales Market Share by Region (2024-2034)
Table 16. Global Insulin Biosimilars Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 17. Global Insulin Biosimilars Sales Quantity Share by Manufacturers (2018-2023)
Table 18. Global Insulin Biosimilars Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 19. Global Insulin Biosimilars Revenue Share by Manufacturers (2018-2023)
Table 20. Global Insulin Biosimilars Price by Manufacturers 2018-2023 (USD/Unit)
Table 21. Global Key Players of Insulin Biosimilars, Industry Ranking, 2021 VS 2024
Table 22. Global Insulin Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Insulin Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Insulin Biosimilars as of 2024)
Table 24. Global Key Manufacturers of Insulin Biosimilars, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Insulin Biosimilars, Product Offered and Application
Table 26. Global Key Manufacturers of Insulin Biosimilars, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Insulin Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
Table 29. Global Insulin Biosimilars Sales Quantity by Type (2024-2034) & (K Units)
Table 30. Global Insulin Biosimilars Sales Quantity Share by Type (2018-2023)
Table 31. Global Insulin Biosimilars Sales Quantity Share by Type (2024-2034)
Table 32. Global Insulin Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 33. Global Insulin Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Insulin Biosimilars Revenue Share by Type (2018-2023)
Table 35. Global Insulin Biosimilars Revenue Share by Type (2024-2034)
Table 36. Insulin Biosimilars Price by Type (2018-2023) & (USD/Unit)
Table 37. Global Insulin Biosimilars Price Forecast by Type (2024-2034) & (USD/Unit)
Table 38. Global Insulin Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
Table 39. Global Insulin Biosimilars Sales Quantity by Application (2024-2034) & (K Units)
Table 40. Global Insulin Biosimilars Sales Quantity Share by Application (2018-2023)
Table 41. Global Insulin Biosimilars Sales Quantity Share by Application (2024-2034)
Table 42. Global Insulin Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 43. Global Insulin Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Insulin Biosimilars Revenue Share by Application (2018-2023)
Table 45. Global Insulin Biosimilars Revenue Share by Application (2024-2034)
Table 46. Insulin Biosimilars Price by Application (2018-2023) & (USD/Unit)
Table 47. Global Insulin Biosimilars Price Forecast by Application (2024-2034) & (USD/Unit)
Table 48. North America Insulin Biosimilars Revenue by Company (2018-2023) & (US$ Million)
Table 49. North America Insulin Biosimilars Sales Quantity by Company (2018-2023) & (K Units)
Table 50. North America Insulin Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
Table 51. North America Insulin Biosimilars Sales Quantity by Type (2024-2034) & (K Units)
Table 52. North America Insulin Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 53. North America Insulin Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Insulin Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
Table 55. North America Insulin Biosimilars Sales Quantity by Application (2024-2034) & (K Units)
Table 56. North America Insulin Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 57. North America Insulin Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Insulin Biosimilars Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 59. North America Insulin Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 60. North America Insulin Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Insulin Biosimilars Sales Quantity by Country (2018-2023) & (K Units)
Table 62. North America Insulin Biosimilars Sales Quantity by Country (2024-2034) & (K Units)
Table 63. Europe Insulin Biosimilars Sales Quantity by Company (2018-2023) & (K Units)
Table 64. Europe Insulin Biosimilars Revenue by Company (2018-2023) & (US$ Million)
Table 65. Europe Insulin Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
Table 66. Europe Insulin Biosimilars Sales Quantity by Type (2024-2034) & (K Units)
Table 67. Europe Insulin Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 68. Europe Insulin Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Insulin Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
Table 70. Europe Insulin Biosimilars Sales Quantity by Application (2024-2034) & (K Units)
Table 71. Europe Insulin Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 72. Europe Insulin Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Insulin Biosimilars Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 74. Europe Insulin Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 75. Europe Insulin Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Insulin Biosimilars Sales Quantity by Country (2018-2023) & (K Units)
Table 77. Europe Insulin Biosimilars Sales Quantity by Country (2024-2034) & (K Units)
Table 78. China Insulin Biosimilars Sales Quantity by Company (2018-2023) & (K Units)
Table 79. China Insulin Biosimilars Revenue by Company (2018-2023) & (US$ Million)
Table 80. China Insulin Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
Table 81. China Insulin Biosimilars Sales Quantity by Type (2024-2034) & (K Units)
Table 82. China Insulin Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 83. China Insulin Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Insulin Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
Table 85. China Insulin Biosimilars Sales Quantity by Application (2024-2034) & (K Units)
Table 86. China Insulin Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 87. China Insulin Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Insulin Biosimilars Sales Quantity by Company (2018-2023) & (K Units)
Table 89. APAC Insulin Biosimilars Revenue by Company (2018-2023) & (US$ Million)
Table 90. APAC Insulin Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
Table 91. APAC Insulin Biosimilars Sales Quantity by Type (2024-2034) & (K Units)
Table 92. APAC Insulin Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 93. APAC Insulin Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Insulin Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
Table 95. APAC Insulin Biosimilars Sales Quantity by Application (2024-2034) & (K Units)
Table 96. APAC Insulin Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 97. APAC Insulin Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Insulin Biosimilars Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 99. APAC Insulin Biosimilars Revenue by Region (2018-2023) & (US$ Million)
Table 100. APAC Insulin Biosimilars Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Insulin Biosimilars Sales Quantity by Region (2018-2023) & (K Units)
Table 102. APAC Insulin Biosimilars Sales Quantity by Region (2024-2034) & (K Units)
Table 103. Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity by Company (2018-2023) & (K Units)
Table 104. Middle East, Africa and Latin America Insulin Biosimilars Revenue by Company (2018-2023) & (US$ Million)
Table 105. Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity by Type (2018-2023) & (K Units)
Table 106. Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity by Type (2024-2034) & (K Units)
Table 107. Middle East, Africa and Latin America Insulin Biosimilars Revenue by Type (2018-2023) & (US$ Million)
Table 108. Middle East, Africa and Latin America Insulin Biosimilars Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity by Application (2018-2023) & (K Units)
Table 110. Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity by Application (2024-2034) & (K Units)
Table 111. Middle East, Africa and Latin America Insulin Biosimilars Revenue by Application (2018-2023) & (US$ Million)
Table 112. Middle East, Africa and Latin America Insulin Biosimilars Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Insulin Biosimilars Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Insulin Biosimilars Revenue by Country (2018-2023) & (US$ Million)
Table 115. Middle East, Africa and Latin America Insulin Biosimilars Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity by Country (2018-2023) & (K Units)
Table 117. Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity by Country (2024-2034) & (K Units)
Table 118. Sanofi S.A. Company Information
Table 119. Sanofi S.A. Description and Overview
Table 120. Sanofi S.A. Insulin Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 121. Sanofi S.A. Insulin Biosimilars Product and Services
Table 122. Sanofi S.A. Insulin Biosimilars SWOT Analysis
Table 123. Sanofi S.A. Recent Developments
Table 124. Boehringer Ingelheim Company Information
Table 125. Boehringer Ingelheim Description and Overview
Table 126. Boehringer Ingelheim Insulin Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 127. Boehringer Ingelheim Insulin Biosimilars Product and Services
Table 128. Boehringer Ingelheim Insulin Biosimilars SWOT Analysis
Table 129. Boehringer Ingelheim Recent Developments
Table 130. Eli Lilly & Co. Company Information
Table 131. Eli Lilly & Co. Description and Overview
Table 132. Eli Lilly & Co. Insulin Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 133. Eli Lilly & Co. Insulin Biosimilars Product and Services
Table 134. Eli Lilly & Co. Insulin Biosimilars SWOT Analysis
Table 135. Eli Lilly & Co. Recent Developments
Table 136. Novo Nordisk A/S Company Information
Table 137. Novo Nordisk A/S Description and Overview
Table 138. Novo Nordisk A/S Insulin Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 139. Novo Nordisk A/S Insulin Biosimilars Product and Services
Table 140. Novo Nordisk A/S Insulin Biosimilars SWOT Analysis
Table 141. Novo Nordisk A/S Recent Developments
Table 142. Biocon Company Information
Table 143. Biocon Description and Overview
Table 144. Biocon Insulin Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 145. Biocon Insulin Biosimilars Product and Services
Table 146. Biocon Insulin Biosimilars SWOT Analysis
Table 147. Biocon Recent Developments
Table 148. Geropharm Company Information
Table 149. Geropharm Description and Overview
Table 150. Geropharm Insulin Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 151. Geropharm Insulin Biosimilars Product and Services
Table 152. Geropharm Insulin Biosimilars SWOT Analysis
Table 153. Geropharm Recent Developments
Table 154. Wockhardt Company Information
Table 155. Wockhardt Description and Overview
Table 156. Wockhardt Insulin Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 157. Wockhardt Insulin Biosimilars Product and Services
Table 158. Wockhardt Insulin Biosimilars SWOT Analysis
Table 159. Wockhardt Recent Developments
Table 160. Gan&Lee Pharmaceuticals Company Information
Table 161. Gan&Lee Pharmaceuticals Description and Overview
Table 162. Gan&Lee Pharmaceuticals Insulin Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 163. Gan&Lee Pharmaceuticals Insulin Biosimilars Product and Services
Table 164. Gan&Lee Pharmaceuticals Insulin Biosimilars SWOT Analysis
Table 165. Gan&Lee Pharmaceuticals Recent Developments
Table 166. The United Laboratories International Company Information
Table 167. The United Laboratories International Description and Overview
Table 168. The United Laboratories International Insulin Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 169. The United Laboratories International Insulin Biosimilars Product and Services
Table 170. The United Laboratories International Insulin Biosimilars SWOT Analysis
Table 171. The United Laboratories International Recent Developments
Table 172. Tonghua Dongbao Pharmaceutical Company Information
Table 173. Tonghua Dongbao Pharmaceutical Description and Overview
Table 174. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 175. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product and Services
Table 176. Tonghua Dongbao Pharmaceutical Insulin Biosimilars SWOT Analysis
Table 177. Tonghua Dongbao Pharmaceutical Recent Developments
Table 178. Key Raw Materials Lists
Table 179. Raw Materials Key Suppliers Lists
Table 180. Insulin Biosimilars Distributors List
Table 181. Insulin Biosimilars Customers List
Table 182. Insulin Biosimilars Market Trends
Table 183. Insulin Biosimilars Market Drivers
Table 184. Insulin Biosimilars Market Challenges
Table 185. Insulin Biosimilars Market Restraints
Table 186. Research Programs/Design for This Report
Table 187. Key Data Information from Secondary Sources
Table 188. Key Data Information from Primary Sources
List of Figures
Figure 1. Insulin Biosimilars Product Picture
Figure 2. Global Insulin Biosimilars Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Insulin Biosimilars Market Share by Type in 2024 & 2034
Figure 4. Rapid-Acting Biosimilars Product Picture
Figure 5. Long-Acting Biosimilars Product Picture
Figure 6. Premixed Biosimilars Product Picture
Figure 7. Global Insulin Biosimilars Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 8. Global Insulin Biosimilars Market Share by Application in 2024 & 2034
Figure 9. Type I Diabetes
Figure 10. Type II Diabetes
Figure 11. Insulin Biosimilars Report Years Considered
Figure 12. Global Insulin Biosimilars Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Insulin Biosimilars Revenue 2018-2034 (US$ Million)
Figure 14. Global Insulin Biosimilars Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 15. Global Insulin Biosimilars Sales Quantity 2018-2034 (K Units)
Figure 16. Global Insulin Biosimilars Sales Quantity Market Share by Region (2018-2023)
Figure 17. Global Insulin Biosimilars Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Insulin Biosimilars Sales Quantity YoY (2018-2034) & (K Units)
Figure 19. North America Insulin Biosimilars Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Insulin Biosimilars Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. Europe Insulin Biosimilars Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Insulin Biosimilars Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. China Insulin Biosimilars Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Insulin Biosimilars Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. APAC Insulin Biosimilars Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. Middle East, Africa and Latin America Insulin Biosimilars Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Insulin Biosimilars Sales Quantity in 2024
Figure 29. The Top 10 and Top 5 Players Market Share by Insulin Biosimilars Revenue in 2024
Figure 30. Insulin Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 31. Global Insulin Biosimilars Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Insulin Biosimilars Revenue Market Share by Type (2018-2034)
Figure 33. Global Insulin Biosimilars Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Insulin Biosimilars Revenue Market Share by Application (2018-2034)
Figure 35. North America Insulin Biosimilars Revenue Market Share by Company in 2024
Figure 36. North America Insulin Biosimilars Sales Quantity Market Share by Company in 2024
Figure 37. North America Insulin Biosimilars Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Insulin Biosimilars Revenue Market Share by Type (2018-2034)
Figure 39. North America Insulin Biosimilars Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Insulin Biosimilars Revenue Market Share by Application (2018-2034)
Figure 41. North America Insulin Biosimilars Revenue Share by Country (2018-2034)
Figure 42. North America Insulin Biosimilars Sales Quantity Share by Country (2018-2034)
Figure 43. United States Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Insulin Biosimilars Sales Quantity Market Share by Company in 2024
Figure 46. Europe Insulin Biosimilars Revenue Market Share by Company in 2024
Figure 47. Europe Insulin Biosimilars Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Insulin Biosimilars Revenue Market Share by Type (2018-2034)
Figure 49. Europe Insulin Biosimilars Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Insulin Biosimilars Revenue Market Share by Application (2018-2034)
Figure 51. Europe Insulin Biosimilars Revenue Share by Country (2018-2034)
Figure 52. Europe Insulin Biosimilars Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 54. France Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 58. China Insulin Biosimilars Sales Quantity Market Share by Company in 2024
Figure 59. China Insulin Biosimilars Revenue Market Share by Company in 2024
Figure 60. China Insulin Biosimilars Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Insulin Biosimilars Revenue Market Share by Type (2018-2034)
Figure 62. China Insulin Biosimilars Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Insulin Biosimilars Revenue Market Share by Application (2018-2034)
Figure 64. APAC Insulin Biosimilars Sales Quantity Market Share by Company in 2024
Figure 65. APAC Insulin Biosimilars Revenue Market Share by Company in 2024
Figure 66. APAC Insulin Biosimilars Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Insulin Biosimilars Revenue Market Share by Type (2018-2034)
Figure 68. APAC Insulin Biosimilars Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Insulin Biosimilars Revenue Market Share by Application (2018-2034)
Figure 70. APAC Insulin Biosimilars Revenue Share by Region (2018-2034)
Figure 71. APAC Insulin Biosimilars Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 76. India Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity Market Share by Company in 2024
Figure 78. Middle East, Africa and Latin America Insulin Biosimilars Revenue Market Share by Company in 2024
Figure 79. Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Insulin Biosimilars Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Insulin Biosimilars Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Insulin Biosimilars Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Insulin Biosimilars Revenue Share by Country (2018-2034)
Figure 85. Brazil Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Insulin Biosimilars Revenue (2018-2034) & (US$ Million)
Figure 90. Insulin Biosimilars Value Chain
Figure 91. Insulin Biosimilars Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries